Vnitr Lek 2018, 64(7-8):771-796

Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi

Jiří Widimský jr1,*, Jan Filipovský2, Jiří Ceral3, Renata Cífková4, Aleš Linhart5, Václav Monhart6, Hana Rosolová2, Jitka Seidlerová Mlíková2, Miroslav Souček7, Jindřich Špinar8, Vladimír Tesař9, Jiří Vítovec10, Tomáš Zelinka1
1 III. interní klinika 1. LF UK a VFN v Praze
2 II. interní klinika LF UK a FN Plzeň
3 I. interní kardioangiologická klinika LF UK a FN Hradec Králové
4 Centrum kardiovaskulární prevence 1. LF UK a Thomayerovy nemocnice, Praha
5 II. interní klinika - klinika kardiologie a angiologie 1. LF UK a VFN v Praze
6 Interní klinika 1. LF UK a ÚVN - Vojenská fakultní nemocnice Praha
7 II. interní klinika LF MU a FN u sv. Anny v Brně
8 Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice
9 Nefrologická klinika 1. LF UK a VFN v Praze
10 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně

Received: March 21, 2018; Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J, Filipovský J, Ceral J, Cífková R, Linhart A, Monhart V, et al.. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2018;64(7-8):771-796.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Filipovský J, Widimský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>. Go to original source... Go to PubMed...
    3. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>. Go to original source... Go to PubMed...
    4. Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011; 53(4-5): 220-229. Go to original source...
    5. Linhart A, Ceral J, Filipovský J. Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku. 1. část. Obecné principy. Hypertenze & kardiovaskulární prevence 2016; 5(2): 24-27.
    6. Ceral J, Linhart A, Filipovský J. Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku. 2. část. Měření krevního tlaku v ordinaci. Hypertenze & kardiovaskulární prevence 2016; 5(2): 28-33.
    7. Parati G, Stergiou G, O'Brien E et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32(7): 1359-1366. Dostupné z DOI: <http://dx.doi.org/10.097/HJH.0000000000000221>. Go to original source... Go to PubMed...
    8. Filipovský J, Seidlerová J, Kratochvíl Z et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press 2016; 25(4): 228-234. Dostupné z DOI: <http://dx.doi.org/10.3109/08037051.2015.1134086>. Go to original source... Go to PubMed...
    9. Zelinka T, Widimský J, Ceral J et al. Jak postupovat při podezření na sekundární arteriální hypertenzi. Vnitř Lék 2016; 62(9): 740-745.
    10. Lovell AR, Ernst ME. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep 2017; 19(5): 39. Dostupné z DOI: <http://dx.doi.org/10.1007/s11906-017-0736-z>. Go to original source... Go to PubMed...
    11. Linhart A. Echokardiografické hodnocení strukturálních změn levé komory u hypertenze. Hypertenze & kardiovaskulární prevence 2015; 4(2): 39-43.
    12. Mattace-Raso F, Hofman A, Verwoert GC et al. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31(19): 2338-2350. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehq165>. Epub 2010 Jun 7. Go to original source... Go to PubMed...
    13. Lonn EM, Bosch J, Lopez-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2009-2020. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600175>. Go to original source... Go to PubMed...
    14. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(23): 290-300. Dostupné z DOI: <http://dx.doi.org710.1016/j.amjmed.2008.09.038>. Go to original source... Go to PubMed...
    15. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58(4): 566-572. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.177592>. Go to original source... Go to PubMed...
    16. Gradman AH, Parisé H, Lefebvre P et al. Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients: A Matched Cohort Study. Hypertension 2013; 61(2): 309-318. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.201566>. Go to original source... Go to PubMed...
    17. Group SR, Wright JT Jr, Williamson JD et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-2116. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1511939>. Erratum in A Randomized Trial of Intensive versus Standard Blood-Pressure Control. [N Engl J Med 2017]. Go to original source... Go to PubMed...
    18. Vidal-Petiot E, Ford I, Greenlaw N et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388(10056): 2142-2152. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(16)31326-5>. Go to original source... Go to PubMed...
    19. Roush GC, Ernst ME, Kostis JB et al. Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension 2015; 65(5): 1041-1046. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.05021>. Go to original source... Go to PubMed...
    20. Patel A, Group AC, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(07)61303-8>. Go to original source... Go to PubMed...
    21. Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386(10008): 2059-2068. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(15)00257-3>. Go to original source... Go to PubMed...
    22. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; (3): CD001841. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD001841.pub2>. Go to original source...
    23. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1409077>. Go to original source... Go to PubMed...
    24. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England journal of medicine 2008; 359(23): 2417-2428. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0806182>. Go to original source... Go to PubMed...
    25. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(05)67185-1>. Go to original source... Go to PubMed...
    26. Matsuzaki M, Ogihara T, Umemoto S et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29(8): 1649-1659. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e328348345d>. Go to original source... Go to PubMed...
    27. Yusuf S, Teo KK et al (The ONTARGET Investigators). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-1559. <http://dx.doi.org/10.1056/NEJMoa0801317>. Go to original source... Go to PubMed...
    28. Sundstrom J, Neovius M, Tynelius P et al. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ 2011; 342: d643. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.d643>. Go to original source... Go to PubMed...
    29. Grebla RC, Rodriguez CJ, Borrell LN et al. Prevalence and determinants of isolated systolic hypertension among young adults: the 1999-2004 US National Health And Nutrition Examination Survey. J Hypertens 2010; 28(1): 15-23. <http://dx.doi.org/10.1097/HJH.0b013e328331b7ff>. Go to original source... Go to PubMed...
    30. McEniery CM, Yasmin, Wallace S et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension 2005; 46(1): 221-226. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000165310.84801.e0>. Go to original source... Go to PubMed...
    31. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887-1898. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0801369>. Go to original source... Go to PubMed...
    32. Williamson JD, Supiano MA, Applegate WB et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial. JAMA 2016; 315(24): 2673-2682. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.7050>. Go to original source... Go to PubMed...
    33. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33(2): 195-211. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000000447>. Go to original source... Go to PubMed...
    34. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33(7): 1321-1341. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000000614>. Go to original source... Go to PubMed...
    35. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347-1351. Go to original source... Go to PubMed...
    36. Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163(9): 1069-1075. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.163.9.1069>. Go to original source... Go to PubMed...
    37. Saxby BK, Harrington F, Wesnes KA et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70(19 Pt2): 1858-1866. Dostupné z DOI: <http://dx.doi.org/10.1212/01.wnl.0000311447.85948.78>. Go to original source... Go to PubMed...
    38. [PROGRESS Collaborative Group]. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041. <http://dx.doi.org/10.1016/S0140-6736(01)06178-5>. Erratum in Lancet 2001; 358(9292): 1556 a Lancet 2002; 359(9323): 2120. Go to original source... Go to PubMed...
    39. Group SPSS, Benavente OR, Coffey CS et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382(9891): 507-515. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(13)60852-1>. Erratum in Lancet 2013; 382(9891): 506. Go to original source... Go to PubMed...
    40. Cushman WC, Evans GW, Byington RP et al. [ACCORD Study Group]. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-1585. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001286>. Go to original source... Go to PubMed...
    41. Mancia G, Cannon CP, Tikkanen I et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension 2016; 68(6): 1355-1364. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.07703>. Go to original source... Go to PubMed...
    42. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-1181. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(09)62100-0>. Go to original source... Go to PubMed...
    43. Sinha AD, Agarwal R. Thiazide Diuretics in Chronic Kidney Disease. Curr Hypertens Rep 2015; 17(3): 13. <http://dx.doi.org/10.1007/s11906-014-0525-x>. Go to original source... Go to PubMed...
    44. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Go to original source... Go to PubMed...
    45. Špinar J, Hradec J, Špinarová L et al. Souhrn Doporučených postupů ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor Vasa 2016; 58(5): 597-636. Go to original source...
    46. Ceral J, Habrdová V, Vořišek V et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34(1): 87-90. Dostupné z DOI: <http://dx.doi.org/10.1038/hr.2010.183>. Go to original source... Go to PubMed...
    47. Štrauch B, Petrák O, Zelinka T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-2461. <http://dx.doi.org/10.1097/HJH.0b013e3283652c61>. Go to original source... Go to PubMed...
    48. de Leeuw PW, Bisognano JD, Bakris GL et al. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension 2017; 69(5): 836-843. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.09086>. Go to original source... Go to PubMed...
    49. Fadl Elmula FE, Jin Y, Yang WY et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press 2015; 24(5): 263-274. Dostupné z DOI: <http://dx.doi.org/10.3109/08037051.2015.1058595>. Go to original source... Go to PubMed...
    50. Townsend RR, Mahfoud F, Kandzari DE et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108): 2160-2170. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)32281-X>. Go to original source... Go to PubMed...
    51. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J 2017; 38(15): 1101-1111. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw303>. Go to original source... Go to PubMed...
    52. Conen D, Aeschbacher S, Thijs L et al. Age-specific differences between conventional and ambulatory daytime blood pressure values. Hypertension 2014; 64(5): 1073-1079. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03957>. Go to original source... Go to PubMed...
    53. Mancia G, Bombelli M, Facchetti R et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009; 27(8): 1672-1678. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e32832be5f9>. Go to original source... Go to PubMed...
    54. Mancia G, Bombelli M, Facchetti R et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54(2): 226-232. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.129882>. Go to original source... Go to PubMed...
    55. Mancia G, Bombelli M, Cuspidi C et al. Cardiovascular Risk Associated With White-Coat Hypertension: Pro Side of the Argument. Hypertension 2017; 70(4): 668-675. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.08903>. Go to original source... Go to PubMed...
    56. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25(11): 2193-2198. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e3282ef6185>. Go to original source... Go to PubMed...
    57. Franklin SS, Thijs L, Li Y et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013; 61(5): 964-971. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.00289>. Go to original source... Go to PubMed...
    58. Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev Obstet Gynecol 2008 Fall;1(4):170-178.
    59. Webster LM, Myers JE, Nelson-Piercy C et al. Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy: A Randomized Controlled Trial. Hypertension 2017; 70(5): 915-922. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.09972>. Go to original source... Go to PubMed...
    60. Rolnik DL, Wright D, Poon LC et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377(7): 613-622. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1704559>. Go to original source... Go to PubMed...
    61. Koopmans CM, Bijlenga D, Groen H et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374(9694): 979-988. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(09)60736-4>. Go to original source... Go to PubMed...
    62. McDonald SD, Malinowski A, Zhou Q et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156(5): 918-930. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2008.06.042>. Go to original source... Go to PubMed...
    63. Hodsman GP, Isles CG, Murray GD et al. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) 1983; 286(6368): 832-834. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.